In prophylactic settings, a Ddx21 mutant peptide generated durable anti-tumor immunity and central-memory T-cell expansion in murine lung-cancer vaccination, suggesting preventive or adjuvant opportunities when high-risk lesions are identifiable (144). The gene discussed is DDX21; the disease is neoplasm.